Based on cIMPACT-NOW update 3, diffuse IDH-wildtype gliomas that are histologically lower grade (WHO grade 2 or 3) can be diagnosed as IDH-wildtype glioblastoma based upon presence of epidermal growth factor receptor (EGFR)-amplification and/or promoter mutation in telomerase reverse-transcriptase (TERT) and/or a combination of gain of complete chromosome 7 and loss of complete chromosome 10 [4]. This evidence concerns the gene EGFR and glioma.